gefurulimab

{
  "id": "MLC-T-ONC-013918",
  "term": "gefurulimab",
  "field": "Oncology and biomedicine",
  "definition": "A humanized bispecific VHH antibody directed against terminal complement protein C5 and albumin, with potential anti-inflammatory and immunomodulatory activities. Upon administration, gefurulimab, with its anti-C5 antibody moiety, targets and binds to terminal complement protein C5, thereby blocking the terminal complement pathway of complement activation. This inhibits complement-mediated inflammation and cell lysis. Excessive complement activation plays a key role in various inflammatory and autoimmune diseases, and leads to tissue destruction. The binding of gefurulimab to albumin, with its albumin binding domain, increases its half-life.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/gefurulimab/"
}